94 related articles for article (PubMed ID: 22318849)
21. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 1997 Jun; 65(3):434-6. PubMed ID: 9190971
[TBL] [Abstract][Full Text] [Related]
22. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
23. PARP inhibitors in breast cancer.
Telli ML; Ford JM
Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
[TBL] [Abstract][Full Text] [Related]
24. [Salvage therapy for refractory testicular cancer].
Kawai K; Akaza H
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1129-35. PubMed ID: 8751799
[TBL] [Abstract][Full Text] [Related]
25. Clinical trials in triple negative breast cancer.
Reeder-Hayes KE; Carey LA; Sikov WM
Breast Dis; 2010; 32(1-2):123-36. PubMed ID: 21778571
[TBL] [Abstract][Full Text] [Related]
26. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.
Bosch A; Eroles P; Zaragoza R; Viña JR; Lluch A
Cancer Treat Rev; 2010 May; 36(3):206-15. PubMed ID: 20060649
[TBL] [Abstract][Full Text] [Related]
27. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review).
Kim R; Tanabe K; Uchida Y; Osaki A; Toge T
Oncol Rep; 2002; 9(1):3-9. PubMed ID: 11748447
[TBL] [Abstract][Full Text] [Related]
28. [Cisplatin (platidiam) and the prospects for using complex platinum compounds in the clinical chemotherapy of malignant tumors].
Gorbunova VA
Vopr Onkol; 1989; 35(3):325-30. PubMed ID: 2705315
[TBL] [Abstract][Full Text] [Related]
29. [Molecular bases of platinum-resistance in testicular cancer].
Germà-Lluch JR; Piulats JM
Arch Esp Urol; 2013 Jun; 66(5):524-35. PubMed ID: 23793770
[TBL] [Abstract][Full Text] [Related]
30. Current State of Platinum Complexes for the Treatment of Advanced and Drug-Resistant Breast Cancers.
Biersack B; Schobert R
Adv Exp Med Biol; 2019; 1152():253-270. PubMed ID: 31456188
[TBL] [Abstract][Full Text] [Related]
31. Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer.
Beheshti F; Hassanian SM; Khazaei M; Hosseini M; ShahidSales S; Hasanzadeh M; Maftouh M; Ferns GA; Avan A
J Cell Physiol; 2018 Apr; 233(4):2752-2758. PubMed ID: 28696006
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy.
Zhang J; Fan M; Xie J; Wang Z; Wang B; Zhang S; Wang L; Cao J; Tao Z; Li T; Hu X
Oncotarget; 2015 Dec; 6(40):43135-43. PubMed ID: 26447756
[TBL] [Abstract][Full Text] [Related]
33. Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance.
Baek DW; Park JY; Lee SJ; Chae YS
Yeungnam Univ J Med; 2020 Jul; 37(3):230-235. PubMed ID: 31962039
[TBL] [Abstract][Full Text] [Related]
34. Platinum resistance in breast and ovarian cancer cell lines.
Eckstein N
J Exp Clin Cancer Res; 2011 Oct; 30(1):91. PubMed ID: 21967738
[TBL] [Abstract][Full Text] [Related]
35. A fluorescent probe for investigating the activation of anticancer platinum(IV) prodrugs based on the cisplatin scaffold.
Montagner D; Yap SQ; Ang WH
Angew Chem Int Ed Engl; 2013 Nov; 52(45):11785-9. PubMed ID: 24105908
[No Abstract] [Full Text] [Related]
36. A carrier-free anti-inflammatory platinum (II) self-delivered nanoprodrug for enhanced breast cancer therapy.
Xing L; Yang CX; Zhao D; Shen LJ; Zhou TJ; Bi YY; Huang ZJ; Wei Q; Li L; Li F; Jiang HL
J Control Release; 2021 Mar; 331():460-471. PubMed ID: 33545218
[TBL] [Abstract][Full Text] [Related]
37. Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding.
Irmejs A; Loza P; Skuja E; Gardovskis J
Cureus; 2017 Jul; 9(7):e1455. PubMed ID: 28929039
[TBL] [Abstract][Full Text] [Related]
38. Impressive Response to Concomitant Platinum-based Chemotherapy and Yttrium-90 in a Patient with Heavily Pretreated Triple-negative Breast Cancer Widely Metastasized to the Liver.
Castrellon A; Nguyen SM; Bengoa F; Botero A; Raez LE
Cureus; 2017 Jun; 9(6):e1402. PubMed ID: 28852599
[TBL] [Abstract][Full Text] [Related]
39. [Guidelines for clinical application of platinum drugs in breast cancer (2023 edition)].
Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association
Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):1018-1031. PubMed ID: 38110310
[TBL] [Abstract][Full Text] [Related]
40. Erratum to: platinum-based chemotherapy in triple-negative advanced breast cancer.
Villarreal-Garza C; Khalaf D; Bouganim N; Clemons M; Peña-Curiel O; Baez-Revueltas B; Kiss A; Kassam F; Enright K; Verma S; Pritchard K; Myers J; Dent R
Breast Cancer Res Treat; 2015 Apr; 150(3):697. PubMed ID: 25809091
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
